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ABSTRACT 
Background and aims: In the absence of overt infection, the systemic inflammatory 
response is increasingly recognised as a pathogenetic factor in the circulatory dysfunction of 
advanced cirrhosis. Our aim was to determine whether the neutrophil-to-lymphocyte ratio, a 
marker of systemic inflammation, is predictive of mortality in patients with end stage 
cirrhosis listed for liver transplantation. 
 
Methods: A single centre study of 570 patients listed for first elective single organ liver 
transplantation January 2007-June 2011.  
 
Results: The median listing neutrophil-to-lymphocyte ratio was 2.9 (IQR 1.9-4.7). 
Neutrophil-to-lymphocyte ratio demonstrated a positive correlation with listing serum 
bilirubin (p<0.001), negative correlation with serum sodium (p<0.001), and positive 
correlation with the MELD score (p<0.001). Neutrophil-to-lymphocyte ratio increased with 
increasing severity of ascites (p<0.001). A higher neutrophil count (p<0.001) and lower 
lymphocyte count (p=0.001) were predictors of wait-list death. In a multivariate competing 
risk Cox model, neutrophil-to-lymphocyte ratio remained independently associated with 
mortality (HR 1.10; 95% CI 1.05-1.15, p<0.001). The proportion of patients with a 
neutrophil-to-lymphocyte ratio <2, 2-4.9 and ≥5 who had died by 3-months of listing was 
3%, 13.8% and 37.3%, respectively (p<0.001). After adjusting for MELD, increasing 
increments of neutrophil-to-lymphocyte ratio were predictive of death by 3-months 
(p=0.043). 
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Conclusions: The blood neutrophil-to-lymphocyte ratio, a simple and readily available 
marker of systemic inflammation, is an independent predictor of mortality in patients with 
liver failure listed for liver transplantation. 
 
KEY POINTS BOX 
 
• The ability of the blood neutrophil-to-lymphocyte ratio, a marker of systemic 
inflammation, to predict prognosis in stable patients with end-stage cirrhosis 
listed for transplantation has not been examined previously. 
• We observed that the neutrophil-to-lymphocyte ratio increased with increasing 
severity of liver failure, correlating positively with jaundice, ascites and MELD. 
• In a multivariate competing risk Cox model, neutrophil-to-lymphocyte ratio was 
an independent predictor of wait-list death. 
• Our findings suggest a new prognostic marker to aid wait-list prioritisation and 
organ allocation, and add weight to the hypothesis that low-grade endotoxaemia 
and a systemic inflammatory response play a pathogenetic role in this setting. 
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In the absence of overt infection, the systemic inflammatory response is increasingly 
recognised as a pathogenetic factor in the circulatory dysfunction of advanced cirrhosis. 
Patients with Child-Pugh Class C cirrhosis and ascites demonstrate an increased frequency of 
bacterial translocation, circulating bacterial DNA and raised plasma levels of 
lipopolysaccharide binding protein (LBP) [1,2,3,4,5]. Bacterial translocation is associated 
with nitric oxide overproduction in the mesenteric vasculature of cirrhotic rats, which appears 
to aggravate the arterial vasodilatation [6]. In humans with end stage liver disease there is 
increased mesenteric lymph node tumour necrosis factor–alpha (TNF-α) expression, and 
increased LBP levels are accompanied by greater circulating levels of inflammatory 
mediators and a more pronounced circulatory dysfunction [5,7]. The exaggerated immuno-
haemodynamic derangement is reversed by the administration of norfloxacin [5,8]. 
Moreover, long-term prophylactic antibiotics reduce the incidence of hepatorenal syndrome 
and improve survival, independent of the prevention of infection [9]. It is therefore postulated 
that bacterial translocation and the secondary systemic response exacerbate the pre-existing 
portal hypertensive syndrome, with implications for hepatic function. 
 
Markers of systemic inflammation have been linked with prognosis in patients in this setting. 
Hospitalised cirrhotics with the systemic inflammatory response syndrome (SIRS) have more 
severe hepatic encephalopathy, and are more likely to develop hepatorenal syndrome and 
have non reversible renal dysfunction [10,11,12]. Moreover, the presence of SIRS is 
associated with greater in hospital mortality [10,11,12]. However, the individual parameters 
of SIRS may be influenced by the clinical features of cirrhosis, and the presence or absence 
of SIRS does not always correlate with the systemic inflammatory response in these patients 
[13,14]. An alternative marker of systemic inflammation, c-reactive protein (CRP) has been 
shown to be a superior prognostic marker if persistently elevated [14]. Yet, CRP is 
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synthesised by the liver and is only marginally increased even in patients with active 
infection [14]. Furthermore, CRP is influenced by other factors such as body mass index, 
weight loss, smoking, active alcohol consumption and diabetes [15]. 
 
The studies examining SIRS and CRP as prognostic markers in cirrhosis included patients 
with decompensated disease and a high prevalence of overt infection or acute alcoholic 
hepatitis [10,11,12,13]. Only a single study has evaluated the usefulness of a marker of 
subclinical inflammation in predicting prognosis in stable patients [16]. Biyik et al found that 
in a population of cirrhotics with less advanced disease (mean MELD score 10 and child 
pugh score 7) a greater neutrophil-to-lymphocyte ratio (NLR) was associated with an 
increased risk of long-term death [16]. Neutrophilia occurs in chronic inflammation and 
lymphopenia accompanies malnutrition; increasing NLR has been shown to predict outcome 
in various other disease processes including cardiac disease, malignancy and renal failure 
[17,18,19,20]. To our knowledge the utility of the NLR as a predictor of death in stable 
patients with end stage cirrhosis has not been examined previously.  Our aim was therefore to 
determine whether the NLR, a simple marker of chronic systemic inflammation, is predictive 
of mortality in patients with end stage cirrhosis listed for liver transplantation. 
 
Methods 
This was a single centre study of 570 consecutive adults listed for first elective single-organ 
liver transplantation for chronic liver disease between January 2007 and June 2011. Patients 
transplanted for acute liver failure were not included, and no patient had end stage renal 
disease requiring renal replacement therapy.  
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Institutional approval was obtained (Clinical Audit department, Queen Elizabeth Hospital; 
reference CAB-05300-13). Written patient consent was not required. 
 
Patients were identified from a prospectively collected database. The following variables at 
time of listing for liver transplantation were recorded: age, gender, weight, height, aetiology 
of liver disease, presence of diabetes mellitus, previous variceal haemorrhage, refractory 
ascites and transjugular intra-hepatic porto-systemic shunt (TIPSS); prescription of 
nonselective betablockers, prophylactic antibiotics (the indication for antibiotics was usually 
the secondary prophylaxis of spontaneous bacterial peritonitis, or end-stage liver disease, and 
was clinician dependent) and immunosuppressive medications (the indication for 
immunosuppressive medications was autoimmune disease, predominantly autoimmune liver 
disease and inflammatory bowel disease); laboratory data (serum bilirubin, albumin, 
international normalised ratio (INR), neutrophil count, lymphocyte count, creatinine, serum 
sodium).  
 
Refractory ascites and type 2 hepatorenal syndrome were defined according the International 
Ascites Club criteria [21,22]. The MELD (Model for End Stage Liver Disease) score was 
determined [23]. The UK Score for Patients with End-Stage Liver Disease (UKELD), a 
recently devised scoring system that incorporates serum sodium in addition to the MELD 
variables used routinely in the UK to prioritise graft allocation, was also calculated [24]. 
Glomerular filtration rate (eGFR) was estimated using the Modification of Diet in Renal 
Disease (MDRD) Study 4-variable equation (eGFR = 186 x creatinine(mg/dl)-1.154 x 
age(years)-0.203 x 1.212(if black) x 0.742(if female) [25]. 
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Statistical analyses 
Normally distributed continuous variables and non-parametric continuous variables were 
compared using the Student’s t-test and Mann-Whitney test, respectively. Chi-squared 
analysis or Fisher’s exact test were used for comparison of categorical data. Correlations 
were determined by Spearman’s rank test.  
 
Survival modelling was performed using Cox proportional hazards analysis. The outcome of 
interest was wait-list death. In the first instance traditional Cox modelling was performed 
with patients censored at the time of liver transplantation, removal from the list because of 
clinical improvement or refusal, or last follow-up if still active. Thereafter, competing risk 
Cox regression analysis was used, according to the method of Fine and Gray [26]. In patients 
listed for liver transplantation the outcome transplantation is a competing risk that may 
impact on the probability of death, and vice versa. Competing risk analysis provides event 
specific (death or transplant) hazard ratios that are adjusted for inter-dependence. Competing 
risk analysis is considered the most appropriate statistical method for assessing the 
relationship between covariates and death in patients on a transplant waiting list, whilst 
traditional Cox regression analysis estimates the probability of death in the absence of 
transplantation [27]. In the competing risk analysis patients were censored at the time of 
removal from the list because of clinical improvement or refusal, or last follow-up if still 
active. Clinically relevant variables were included simultaneously in the multivariate models. 
Hyponatraemia was not included because of colinearity. In view of small patient numbers, all 
patients with follow-up beyond 1-year were censored at this time point. 
 
Logistic regression analysis was used to examine the MELD adjusted association between 
NLR and 3-month wait-list mortality. Receiver-operating characteristic (ROC) curves were 
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then generated to assess the accuracy of variables in predicting death by 3-months. To 
examine the impact of the addition of NLR to the MELD and UKELD scores competing risk 
Cox regression of variables transformed into their natural logarithms provided regression 
coefficients. Concordance statistics (c-statistics) were compared using the method described 
by Hanley and McNeil [28]. All patients censored prior to the specified time point were 
excluded from these analyses. 
 
Data was analysed using the SPSS 21 package (SPSS Inc, Chicago, IL, USA) except the 
competing risk analyses, which were performed using Stata 13.1 (Stat Corp, College Station, 
Texas). All values are expressed as mean and standard deviation (SD), median and inter-
quartile range (IQR) and number and percent (%) as appropriate. P<0.05 was considered 
statistically significant at all times. 
 
Results 
Characteristics of the patients at time of listing for liver transplantation are outlined in Table 
1. The mean age was 54.1 (SD 9.9) years and the male to female ratio was 1.8:1. The mean 
listing MELD score was 15 (SD 5).  
 
The median listing neutrophil count was 3.2 (IQR 2.2-4.5) x109/l. Ninety-six patients (17.0%) 
had a neutrophil count below the reference range, and 27 patients (4.8%) had a neutrophil 
count above. The median listing lymphocyte count was 1.1 (0.7-1.5) x109/l. Two hundred and 
twenty-five patients (39.8%) and 1 patient (0.2%) had a lymphocyte count below and above 
the normal range, respectively. The median NLR was 2.9 (IQR 1.9-4.7).  
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Parameters associated with NLR 
There was no relationship between listing NLR and age (r=0.030, p=0.473) or gender (male, 
2.8 (1.8-4.7); female, 3.0 (2.1-4.7), median (IQR), p=0.137). Patients with cholestatic disease 
had a higher NLR than other aetiologies of liver disease (alcoholic liver disease, 3.1 (2.0-4.7); 
hepatitis C, 2.2 (1.5-3.5); cholestatic, 3.7 (2.5-5.7); NAFLD, 2.7 (2.0-4.5) other, 2.8 (1.8-4.5); 
median (IQR), p<0.001). The NLR was lower in patients with hepatocellular carcinoma 
(hepatocellular carcinoma, 2.0 (1.4-2.8); no hepatocellular carcinoma, 3.3 (2.3-5.2); median 
(IQR), p<0.001). 
 
NLR demonstrated a positive correlation with listing serum bilirubin (r=0.277, p<0.001) and 
listing INR (r=0.156, p<0.001), and a negative correlation with listing serum albumin (r=-
0.090, p=0.033). NLR was positively related to serum creatinine (r=0.104, p=0.013), and 
negatively related to eGFR (r=-0.137, p=0.001) and serum sodium (r=-0.453, p<0.001). NLR 
correlated with the MELD (r=0.297, p<0.001) and UKELD scores (r=0.460, p<0.001). The 
median listing NLR increased with increasing severity of ascites (no ascites, 2.2 (1.5-3.2); 
controlled ascites, 3.1 (2.2-4.7); refractory ascites, 4.6 (3.0-6.4); median (IQR), p<0.001, 
Figure 1), and was higher in patients fulfilling the diagnostic criteria for type 2 hepatorenal 
syndrome (hepatorenal syndrome, 4.8 (3.7-8.4); no hepatorenal syndrome 2.9 (1.9-4.6), 
p=0.008).  
 
The use of antibiotic prophylaxis (antibiotics, 3.4 (2.5-5.3); no antibiotics, 2.7 (1.8-4.6); 
median (IQR), p<0.001) and immunosuppressive medications (immunosuppression, 4.8 (2.4-
7.0), no immunosuppression, 2.8 (1.9-4.5); median (IQR), p<0.001) were associated with a 
greater NLR. There was no difference in the median listing NLR of patients prescribed 
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NSBB (2.2 (IQR 2.0-4.5)) compared to patients not prescribed NSBB (2.9 (IQR 1.9-4.7), 
p=0.893).  
 
NLR and wait-list mortality 
Eighty-seven patients (15.3%) died and 410 patients (71.9%) were transplanted during a 
median followup time of 77 (IQR 27-199) days. The estimated 3-month, 6-month and 12-
month survival was 89.0%, 79.8% and 65.0%, respectively. The documented causes of death 
were liver failure (52 patients), multi-organ failure cause unspecified (10 patients), sepsis (9 
patients), cardiac (4 patients), hepatocellular carcinoma (3 patients) and other (9 patients). 
 
Variables associated with wait-list death on univariate analysis are presented in Table 2. A 
higher neutrophil count (p<0.001) and lower lymphocyte count (p=0.001) were predictors of 
mortality within 1 year of listing. The greater the NLR, the greater the risk of death 
(p<0.001). 
 
In a multivariate competing risk Cox model, NLR was independently associated with wait-
list mortality (HR 1.10; 95% CI 1.05-1.15, p<0.001, Table 3 and Figure 2). Other variables 
associated with death were MELD score (p=0.007) and refractory ascites (p=0.010). The 
higher the NLR, the lower the likelihood of transplantation (p=0.023). Substitution of MELD 
with UKELD in the multivariate model did not affect the statistical relationship between 
NLR and mortality (HR 1.08; 95% CI 1.03-1.13, p=0.001, model not shown). NLR remained 
independently associated with wait-list death in the following subgroups of patients: absence 
of hepatocellular carcinoma, presence of hepatocellular carcinoma, refractory ascites, no 
refractory ascites, listing MELD ≥18, listing MELD <18 (Table 4).  
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NLR and 3-month mortality 
263 patients (46.1%) and 44 patients (7.7%) were transplanted or had died by 3-months after 
listing. The listing neutrophil count was higher in patients who died (dead, 4.6 (2.6-7.0); 
alive, 3.1 (2.1-4.0); median (IQR), p<0.001), and the listing lymphocyte count was lower 
(dead, 1.0 (0.6-1.3); alive, 1.0 (0.7-1.5); median (IQR), p=0.018). The median listing NLR of 
the non surviving patients was 4.7 (IQR 2.8-8.8) and for the surviving patients was 2.8 (IQR 
2.0-4.5, p<0.001, Figure 3).  
 
The proportion of patients with a listing NLR <2, 2-4.9, and ≥5 who had died within 3-
months was 3%, 13.8% and 37.3%, respectively (p<0.001). After adjusting for MELD, 
increasing increments of NLR were associated with greater 3-month mortality (NLR <2, OR 
1.00; NLR 2-4.9, OR 3.17 (95% CI 0.70-14.37); NLR ≥5, OR 6.02 (95% CI 1.28-28.41), 
p=0.043). 
 
The c-statistic for the listing NLR for predicting death by 3-months was 0.709 (95% CI 
0.624-0.794). The addition of NLR to MELD increased the c-statistic from 0.768 (95% CI 
0.689-0.847) to 0.792 (95% CI 0.716-0.868, p=0.579). The addition of NLR to UKELD did 
not affect the c-statistic for predicting 3-month death (UKELD alone, 0.821 (95% CI 0.749-
0.892); UKELD and NLR, 0.820 (95% CI 0.750-0.890). 
 
Discussion 
In this large single centre study we have examined for the first time the ability of the blood 
NLR, a simple marker of systemic inflammation, to predict prognosis in stable patients with 
end stage cirrhosis listed for liver transplantation. We have made two important observations. 
Firstly, the NLR increases with increasing severity of liver failure. We observed that the NLR 
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correlated positively with jaundice, ascites and MELD, and the higher the NLR the greater 
was the risk of death. This supports the hypothesis that subclinical inflammation is a 
pathogenetic factor in advanced liver disease. Secondly, the NLR is a useful prognostic 
indicator in patients listed for liver transplantation. In a multivariate competing risk Cox 
model, listing NLR predicted wait-list mortality independent of the MELD score. 
 
In contrast to previous studies of markers of systemic inflammation in advanced cirrhosis, our 
findings were made in the absence of acute decompensation precipitated by for example 
infection or acute alcoholic hepatitis [10,11,12,14]. In stable cirrhotic patients the prevalence 
of circulating bacterial DNA has been reported to be approximately 40% [29,30]. Low dose 
endotoxaemia without clinical signs or symptoms is associated with a systemic inflammatory 
response, and induces a rise in blood neutrophil count and fall in total lymphocyte count [31]. 
Therefore, in cirrhosis the increased NLR may be an indicator of subclinical endotoxaemia. 
Lymphocytopenia is also a well recognised sequelae of malnutrition. The high prevalence of 
lymphocytopenia in our patients, and the association of a lower lymphocyte count with 
mortality, may have at least in part been a consequence of poor nutritional status [20,32]. 
 
A greater listing NLR was associated with more severe liver failure, as demonstrated by a 
higher serum bilirubin level, INR and MELD score. Moreover, an increasing NLR was 
related to the severity of ascites, hyponatraemia and renal dysfunction. Our study does not 
clarify whether the systemic inflammatory response contributes to the hepatic and circulatory 
dysfunction of cirrhosis, or is a secondary phenomenon and a surrogate marker of advanced 
disease. However, the previous observation that norfloxacin administration in ascitic patients 
increased vascular resistance, in the context of normalisation of plasma LBP and reduced 
cytokine levels, is consistent with an active role [5,8]. Further support for this theory is 
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provided by Fernandez et al’s randomised controlled trial in which long-term prophylactic 
antibiotics reduced the incidence of hepatorenal syndrome and improved survival, 
independent of the prevention of infection [9]. 
 
Blood NLR has been linked with outcome in other aspects of liver disease. In patients with 
hepatocellular carcinoma, the NLR correlates with tumour stage, and a greater NLR has been 
shown to be related to non response to treatment, tumour recurrence, all-cause mortality and 
post liver transplantation death [33,34,35,36,37]. Similarly, in patients receiving 
chemotherapy or undergoing resection of colorectal liver metastasis, a higher NLR was 
associated with an increased mortality risk [38,39]. Only one paper has examined the role of 
NLR for staging severity of liver disease: in patients undergoing liver biopsy for a clinical 
suspicion of non-alcoholic fatty liver disease the NLR was predictive of the presence of 
steatohepatitis and fibrosis [40].  
 
The majority of deaths in this series were as a result of liver failure or sepsis. We hypothesise 
that the increased NLR in our patients was a sign of subclinical endotoxaemia, and that the 
relationship between increasing NLR and death reflected the role that the systemic 
inflammatory response plays in the hepato-circulatory dysfunction of advanced liver disease. 
It should be mentioned that blood NLR has also been shown to be a marker of worse outcome 
in other disease processes where chronic inflammation has pathogenetic significance. In 
particular, the NLR has recently emerged as a risk stratification tool in cardiovascular 
disease. An elevated NLR is associated with arterial stiffness and the coronary artery 
calcification score, and is a poor prognostic indicator in acute coronary syndrome and stable 
coronary artery disease [17]. It is postulated that neutrophils have a causal link in such 
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conditions. Following on from this, in patients scheduled for angiography the blood 
neutrophil count outperformed CRP as a predictor of cardiovascular mortality [41].  
 
The main limitation of this study is the NLR was calculated from a single blood sample taken 
at the time of listing for transplantation. It is possible that low grade infection could have 
been undiagnosed, and impacted on the association between NLR and death. However, our 
unit has a high suspicion for infection in cirrhotic patients, and infection is a contraindication 
to activation on the transplant waiting list. Moreover, the incidence of death increased 
linearly over a prolonged follow-up time period.   
 
The clinical implications of our findings are two-fold. Firstly, NLR is predictive of liver 
transplant wait-list mortality, independent of current scoring systems. In an era of organ 
shortage and growing wait-list death tools to optimise wait-list prioritisation and organ 
allocation are necessary. Our findings support the use of the NLR as a prognostic marker in 
this setting. Secondly, interventions that modify the systemic inflammatory response are 
likely to be beneficial. Prophylactic antibiotics in high risk individuals may reduce the 
incidence of circulatory complications and prolong survival to transplantation [9].  
 
In conclusion, in this large single centre study we have shown for the first time that a simple 
and readily available marker of systemic inflammation, the NLR, is an independent predictor 
of mortality in patients with liver failure listed for liver transplantation. Our findings suggest 
a new prognostic marker to aid wait-list prioritisation and organ allocation, and add weight to 
the hypothesis that low grade endotoxaemia and a systemic inflammatory response play a 
pathogenetic role in end stage cirrhosis. 
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Table 1: Characteristics of all patients at time of listing for liver transplantation  
  
n:570 
 
Age (years) 
Male gender 
Body mass index (kg/m2) 
Diagnosis: 
     Alcohol 
     Hepatitis C 
     Cholestatic 
     NAFLD 
     Other 
Hepatocellular carinoma 
Diabetes mellitus 
Blood parameters at listing: 
     Bilirubin (μmol/l) 
     Albumin (g/l) 
     INR 
     Creatinine (μmol/l) 
     eGFR (ml/min/1.73m2) 
     Sodium (mmol/l) 
     Neutrophil count (x109/l) 
     Lymphocyte count (x109/l) 
NLR 
MELD score 
UKELD score 
Previous variceal haemorrhage 
Ascites 
Refractory ascites  
Hepatorenal syndrome (type 2) 
Nonselective beta-blockers 
Prophylactic antibiotics 
Immunosuppressive medications 
TIPSS 
 
54.1(9.9) 
365(64.0) 
27.7(10.1) 
 
145(25.4) 
123(21.6) 
154(27.0) 
54(9.5) 
94(16.5) 
148(26.0) 
133(23.5) 
 
48(25-102) 
33(7) 
1.3(1.2-1.6) 
87(25) 
88(31) 
138(134-141) 
3.2(2.2-4.5) 
1.1(0.7-1.5) 
2.7(1.9-4.7) 
15(5) 
54(6) 
133(23.3) 
356(62.5) 
129(22.6) 
9(1.6) 
212(39.0) 
123(21.6) 
43(7.5) 
25(4.4) 
Values expressed as mean (standard deviation), median (interquartile range) and number (percent) where appropriate 
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Table 2: Univariate cox regression analyses of variables associated with death after listing 
for liver transplantation. 
  Cox regression analysis 
Outcome death (censored at 
transplant) 
Competing risk Cox 
regression analysis 
Outcome Death 
  HR 95% CI P value HR 95% CI P value 
Age ≥60 years 
Female gender 
Blood group 
 
Hepatocellular 
carcinoma 
eGFR <60 
ml/min/1.73m2 
Hyponatraemia 
Refractory ascites 
MELD score 
UKELD score 
Neutrophil count 
(x109/l) 
Lymphocyte count 
(x109/l) 
NLR 
 
 
A 
B/AB 
 
 
 
 
 
 
0.98 
0.65 
1.18 
1.08 
0.64 
1.53 
3.31 
2.59 
1.14 
1.16 
1.22 
0.58 
1.14 
0.63-
1.53 
0.41-
1.03 
0.74-
1.90 
0.60-
1.95 
0.35-
1.18 
0.95-
2.47 
2.17-
5.06 
1.69-
3.96 
1.09-
1.19 
1.12-
1.21 
1.13-
1.31 
0.39-
0.88 
1.09-
1.19 
0.943 
0.066 
0.490 
0.808 
0.151 
0.079 
<0.001 
<0.001 
<0.001 
<0.001 
<0.001 
0.011 
<0.001 
1.21 
0.75 
1.22 
1.40 
0.43 
1.72 
2.78 
2.64 
1.07 
1.10 
1.16 
0.52 
1.14 
0.78-
1.87 
0.47-
1.19 
0.76-
1.95 
0.77-
2.54 
0.23-
0.78 
1.07-
2.76 
1.83-
4.24 
1.72-
4.05 
1.03-
1.10 
1.06-
1.14 
1.08-
1.25 
0.36-
0.76 
1.10-
1.18 
0.402 
0.217 
0.419 
0.265 
0.006 
0.026 
<0.001 
<0.001 
<0.001 
<0.001 
<0.001 
0.001 
<0.001 
Reference group (relative risk 1.00): age <60 years, male gender, blood group O, no hepatocellular carcinoma, body mass 
index ≤30, eGFR ≥60 ml/min/1.73m2, no hyponatraemia, no refractory ascites. 
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Table 3: Multivariate cox regression analyses of variables associated with death after listing 
for liver transplantation. 
 
 
Cox regression 
analysis 
Competing risk Cox regression analysis 
 
Outcome death 
(censored at transplant) 
Outcome Death Outcome Transplant
 
HR(95% 
CI) 
P value
HR(95% 
CI) 
P value
HR(95% 
CI) 
P 
value 
Age ≥60 years 
Female gender 
Blood group 
 
Hepatocellular 
carcinoma 
eGFR <60 
ml/min/1.73m2 
Refractory 
ascites 
MELD score 
NLR 
 
 
A 
B/AB 
 
 
 
1.36(0.83-
2.24) 
0.78(0.48-
1.28) 
0.93(0.57-
1.52) 
0.80(0.43-
1.49) 
1.71(0.85-
3.41) 
1.01(0.60-
1.70) 
2.32(1.43-
3.75) 
1.15(1.10-
1.21) 
1.10(1.05-
1.16) 
0.223 
0.328 
0.769 
0.475 
0.131 
0.958 
0.001 
<0.001 
<0.001 
1.47(0.88-
2.43) 
0.70(0.44-
1.13) 
1.06(0.64-
1.77) 
1.29(0.68-
2.44) 
0.76(0.38-
1.52) 
1.26(0.76-
2.10) 
1.89(1.16-
3.08) 
1.06(1.01-
1.10) 
1.10(1.05-
1.15) 
0.139 
0.149 
0.812 
0.437 
0.439 
0.377 
0.010 
0.007 
<0.001 
0.80(0.64-
1.02) 
1.15(0.93-
1.43) 
0.97(0.78-
1.20) 
0.64(0.47-
0.86) 
2.10(1.60-
2.75) 
0.81(0.60-
1.10) 
0.94(0.71-
1.25) 
1.03(1.01-
1.06) 
0.95(0.90-
0.99) 
0.069 
0.197 
0.761 
0.003 
<0.001 
0.171 
0.688 
0.005 
0.023 
 
Reference group (relative risk 1.00): age <60 years, male gender, blood group O, eGFR ≥60 ml/min/1.73m2, no refractory 
ascites. 
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Table 4: Association between NLR and wait-list mortality on competing risk analysis in 
patient subgroups 
Subgroups No. Median NLR (IQR) Competing risk cox regression analysis 
 
   *Adjusted HR (95% CI) P value 
No hepatocellular 
carcinoma 
Hepatocellular 
carcinoma 
No refractory ascites 
Refractory ascites 
MELD <18 
MELD ≥18 
422 
148 
441 
129 
371 
151 
3.3(2.3-5.2) 
2.0(1.4-2.8) 
2.6(1.8-4.0) 
4.6(3.0-6.4) 
2.7(1.8-4.2) 
3.6(2.5-5.8) 
1.11(1.07-1.16) 
1.47(1.17-1.84) 
1.14(1.05-1.25) 
1.08(1.03-1.14) 
1.15(1.06-1.24) 
1.13(1.08-1.19) 
<0.001 
0.001 
0.003 
0.002 
0.001 
<0.001 
 *Adjusted for age ≥60 years, gender, blood group and MELD score 
 
 
Figure 1: Box plot of listing NLR in patients subdivided according to severity of ascites. 
 
Figure 2: Cumulative incidence of death in patients with listed for liver transplantation 
subdivided based on the NLR; 0-1.9 solid black line, 2-4.9 dash line, ≥5 solid grey line 
(truncated at 365 days). Cumulative incidence calculated using competing risk analysis and 
adjusted for age, gender, blood group, hepatocellular carcinoma, eGFR <60 ml/min/1.73m2, 
refractory ascites and MELD score. 
 
Figure 3: Box-plot of NLR in surviving and non surviving patients by 3-months after listing 
for liver transplantation. 
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